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Antiretroviral concentration measurements 
as an additional tool to manage virologic failure 
in resource limited settings: a case control study
Allan Buzibye1*, Joseph Musaazi1, Amrei von Braun2, Sarah Nanzigu3, Christine Sekaggya‑Wiltshire1, 
Andrew Kambugu1, Jan Fehr4, Mohammed Lamorde1, Ursula Gutteck5, Daniel Muller5, Stefanie Sowinski6, 
Steven J. Reynolds7,8 and Barbara Castelnuovo1
Abstract 
Background: Several studies demonstrate a correlation between sub‑therapeutic concentrations of antiretroviral 
drugs and virologic failure. We examined the sensitivity, specificity and predictive values of sub‑therapeutic drug 
levels in predicting viralogic failure.
Methods: This was a case control study with cases being samples of participants with virologic failure, and controls 
samples of participants with virologic suppression. We analyzed samples obtained from participants that had been on 
antiretroviral treatment (ART) for at least 6 months. Virologic failure was defined as HIV‑RNA viral load ≥ 1000 copies/
ml. Sub‑therapeutic drug levels were defined according to published reference cutoffs. The diagnostic validity of drug 
levels for virologic failure was assessed using plasma viral loads as a gold standard.
Results: Sub‑therapeutic ART concentrations explained only 38.2% of virologic failure with a probability of experi‑
encing virologic failure of 0.66 in a patient with low drug levels versus 0.25 for participants with measurements within 
or above the normal range. Approximately 90% of participants with ART concentrations above the lower clinical cut 
off did not have virologic failure.
Conclusions: These results support prior indication for therapeutic drug monitoring in cases of suspected virologic 
failure.
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Background
Antiretroviral therapy (ART) has reduced morbidity and 
mortality in people living with HIV [1, 2]. Currently, the 
World Health Organization recommends periodic viral 
load testing for monitoring the effectiveness of ART [3]. 
Virologic failure is defined according to the 2016 WHO 
guidelines as two consecutive HIV-RNA viral loads 
≥ 1000  copies/ml [3]. Patients with an initial detectable 
viral load test result receive intensive adherence counsel-
ling sessions before the viral load test is repeated, in order 
to differentiate non-adherence to ART from virologic 
failure due to drug resistance. When the repeat viral load 
result remains ≥ 1000 copies/ml patients are switched to 
another regimen.
Two factors that may contribute to virologic failure 
include pre-treatment resistance and acquired drug 
resistance [4, 5]. Acquired drug resistance normally 
results from sub-therapeutic drug exposure. Factors 
that may lead to sub-therapeutic exposure include single 
nucleotide polymorphisms [4, 5], drug–drug interactions, 
drug–herb interactions, non-adherence and mal-absorp-
tion [6–9]. Therapeutic drug monitoring (TDM) may 
detect suboptimal concentrations, and therefore inform 
the clinicians on the need to address factors which may 
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lead to drug resistance and prevent unnecessary switch-
ing where treatment options are already limited.
Therapeutic drug monitoring is the clinical practice 
of measuring specific drug levels at designated intervals 
with the purpose of maintaining a constant blood con-
centration and optimize dosage for individual patients 
[10]. Among the antiretroviral drug classes, non-nucleo-
side reverse transcriptase inhibitors (NNRTIs) and pro-
tease inhibitors (PIs) meet the proposed criteria for TDM 
such as the presence of a dose–response relationship 
[11]. Several platforms are employed for TDM of HIV 
drugs [12–14]. In resource-limited settings, high perfor-
mance liquid chromatography with ultraviolet detection 
(HPLC-UV) is commonly used. We investigated the sen-
sitivity, specificity and predictive values of NNRTIs and 
PIs drug levels in predicting virologic failure.
Materials and methods
This study was conducted at the Infectious Diseases 
Institute (IDI), Makerere University, an HIV centre of 
excellence located in Mulago teaching Hospital in Kam-
pala with over 8000 HIV-positive individuals receiving 
care [15]. The IDI clinic began providing HIV care in 
2002, while free ART has been provided since April 2004.
This was a case control study. For our analysis we used 
samples from patients enrolled in the “Resistance in HIV-
infected adults in North and South” (RHINOS) study 
[16]. The RHINOS study was conducted between June 
and September 2015 at IDI, and enrolled patients on any 
first- or second-line ART regimen for at least 6 months. 
The RHINOS study offered viral load testing to all partic-
ipants and resistance testing to those with VL > 1000 cop-
ies/ml [16].
Cases were defined as participants with virologic fail-
ure (VL > 1000  copies/ml), while controls were patients 
with a measurement of VL ≤ 1000 copies. Controls 
were matched on age and gender at the ratio of 1:2, and 
samples were obtained using the cumulative sampling 
technique.
An in-house multiplex assay high performance liq-
uid chromatography with ultraviolet detection (HPLC-
UV) was developed and validated to measure the serum 
concentration of efavirenz, nevirapine, atazanavir and 
lopinavir. The HPLC UV system used was a Shimadzu 
LC-2010HT with an inbuilt auto sampler, pumps, and 
UV detector (Shimadzu, Kyoto, Japan), controlled by 
CLASS-VP software version 6.1 (Shimadzu, Kyoto, 
Japan). The analytical phenyl hexyl column was a Betasil 
150 ×  3 mm, 5 µm (Thermo Scientific, Waltham, USA) 
protected by an inline filter. Sample processing involved 
protein precipitation from serum. Dual detection was 
achieved at 210 and 254 nm. The mobile phase consisted 
of 50  mM ammonium acetate/0.1  mmol/l EDTA/0.1% 
formic acid and acetonitrile/water (9/1 v/v). The flow rate 
was set at 0.45 ml/min with gradient elution. The method 
was validated over a concentration range of 1–15  mg/l 
for nevirapine, efavirenz, lopinavir and 0.2–3  mg/l for 
atazanavir. The assay was accurate (98.0–109.6%) with 
inter and intra-day coefficient of variation less than 11%. 
Drug levels were considered sub-therapeutic if they were 
below the lower clinical cut-off [17–19].
Serum concentration data were captured using Epi-
Data version 3.1 (EpiData association, Odense, Den-
mark). Serum data were merged with other data collected 
from the main RHINOS study dataset and analyzed 
using STATA/IC version 14.2 (StataCorp, College Sta-
tion, Texas 77845 USA). McNemar’s Chi-square test was 
used to compare categorical characteristics across cases 
and controls, such as WHO stage. Mann–Whitney Wil-
coxon rank-sum test was used for continuous variables, 
like CD4 counts, and serum drug concentrations. Sensi-
tivity, specificity and predictive values (PV) of drug lev-
els in predicting virologic failure was estimated. Receiver 
operating characteristic (ROC) curve analysis was used 
to define a cut-off that would provide a maximum value 
for specificity and sensitivity.
Results
Of 2511 patients enrolled in RHINOS, 198 (7.9%) patients 
had VL > 1000 copies/ml, and were eligible as cases; two 
cases were excluded because they had no matching con-
trols, and five other cases were excluded because samples 
could not be identified. Therefore, 191 cases and 382 con-
trols for a total of 573 samples were analyzed for serum 
drug levels.
Table  1 compares the baseline characteristics of the 
cases and the controls. The median CD4 count was 
lower in the cases (262  cells/µl,) compared to the con-
trols (500  cells/µl,) (P-value < 0.01). Cases had a higher 
proportion of participants in WHO 3 or 4 stage, com-
pared to controls (61.8% versus 51.2%, P-value = 0.02). 
We observed a higher proportion of cases on PI-based 
ART regimen compared to controls (25.7% versus 11.8%, 
P-value < 0.01). Cases were matched with controls by 
gender and age, and therefore, baseline differences were 
mainly observed in WHO staging and CD4 counts. The 
average time from the last intake of a dose of ART was 
8 h.
For nevirapine, efavirenz and atazanavir, mean and 
the median drug concentrations were significantly 
lower in the cases compared to controls. For lopinavir a 
trend towards lower concentrations was noted in cases 
(Table  2). Most drug levels were within the published 
clinical ranges for all the drugs (Fig. 1).
Overall, TDM had a sensitivity of 38.2% and a posi-
tive predictive value (PPV) of 65.8% for virologic failure. 
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Sensitivity, specificity, PPV and negative predictive value 
(NPV) respectively for each drug are shown in Table  3. 
Using ROC curve analysis, for nevirapine, a cut off of 
7.8  mg/l resulted in a sensitivity of 78% and a specific-
ity of 56% (AUC-0.71). For efavirenz, a cut off of 2.7 mg/l 
resulted in a sensitivity of 64% and a specificity of 54% 
(AUC-0.61). Sample size was inadequate to establish a 
cut-off for atazanavir. No calculation was performed for 
lopinavir as there was no significant difference in concen-
trations between cases and controls.
Discussion
Previous studies have shown a positive relationship 
between drug levels and virologic failure [19–22]. How-
ever, to our knowledge this is the first sub-Saharan Africa 
study to explore the sensitivity, specificity and predictive 
values of a panel of non-nucleoside reverse transcriptase 
inhibitors and protease inhibitors for predicting viro-
logic failure. Serum concentrations of ART among cases 
were significantly lower than concentrations among con-
trols suggesting that low drug levels contribute to viro-
logic failure. We show that an approach using TDM as a 
screening tool would identify approximately one third of 
the cases of virologic failure in our study population.
A patient with a low level of ART was more likely to 
be experiencing virologic failure compared to a patient 
Table 1 Patients’ characteristics by cases and controls
Gender and age were used as matching variables, so P-values on them is not relevant
N number, IQR interquartile range, VL viral load, WHO World Health Organization, ART antiretroviral therapy, ATV atazanavir, LPV lopinavir, EFV efavirenz, NVP 
nevirapine, NNRTI nonnucleoside reverse transcriptase inhibitor, PI protease inhibitor
Characteristics Cases (VL > 1000) (copies/µl) 
N = 191
Controls (VL ≤ 1000) (copies/µl) 
N = 382
P-value
N (%) N (%)
Gender, number (%)
 Male 58 (30.4) 116 (30.4) –
 Female 133 (69.6) 266 (69.6) –
Age in years, median (IQR) 37 (29−43) 37 (29−43) –
 18–34 75 (39.3) 150 (39.3) –
 ≥ 35 116 (60.7) 232 (60.7) –
WHO stage, number (%)
 1 or 2 73 (38.2) 186 (48.8) 0.02
 3 or 4 118 (61.8) 195 (51.2)
CD4 cell counts per µl, median (IQR) 262 (118−429) 500 (346−661) < 0.01
Duration on ART in months, median (IQR) 47 (27−82) 46 (27−93) 0.22
Time since HIV diagnosis in years Median (IQR) 7 (3−11) 8 (4−11) 0.30
ART_NNRT (NVP, EFV), number (%) 141 (74.2) 339 (88.7) –
ART_PI (ATV, LPV), number (%) 49 (25.7) 45 (11.8) < 0.01
Table 2 Distribution of  drug concentrations by  cases 
and controls
*P-values comparing median drug concentrations between cases and controls 
using Mann–Whitney Wilcoxon rank-sum test. Significant differences were 
observed in concentrations of nevirapine, efavirenz and atazanavir
Drug Cases Controls P-value*
N Median (IQR) N Median (IQR)
Nevirapine 65 5.37 (2.81–7.64) 116 8.18 (6.38–12.69) < 0.01
Efavirenz 77 1.60 (0.00–2.50) 221 2.72 (1.78–4.71) < 0.01
Lopinavir 34 6.41 (0.00–10.70) 24 9.84 (5.54–13.57) 0.06
Atazanavir 15 0.00 (0.00–1.44) 21 2.50 (1.29–3.24) 0.01
Fig. 1 A box plot of drug concentration by drug type stratified by 
cases and controls. x = Marks the lower and upper cut‑off of normal 
ranges
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with higher concentrations. Generally, the predictive val-
ues were 70% or higher except for efavirenz whose PPV 
was 57.1% and lopinavir whose NPV was 51.3%. Here we 
report a higher PPV for efavirenz compared to what was 
reported earlier by Catia and colleagues (50%) [19] prob-
ably due to a higher prevalence of virologic failure in our 
setting compared to the Swiss setting. Our study identi-
fied greater sensitivity and specificity when using lower 
cutoffs for nevirapine (7.8 mg/l) and efavirenz (2.7 mg/l) 
that were greater than previously published cutoffs (nevi-
rapine 3  mg/l and efavirenz (1  mg/l). Our cut-offs are 
likely influenced by a greater proportion of participants 
with high concentrations of NNRTI (Fig.  1) that may 
be explained by slow metabolizer polymorphisms of 
cytochrome P450 2B6 that are more common in African 
settings [23].
Our results confirm previous findings about the per-
formance of TDM in predicting virologic failure when 
compared with viral load measurements [24]. TDM has 
been reported to be a poor predictor of virologic failure 
compared to other adherence measures such as alec-
tronic adherence monitoring device and pharmacy refill 
[24–26]. However, TDM performs far better than self-
reported adherence. In a study done in Cameroon [27], 
virologic failure was associated with nevirapine concen-
tration but not with self-reported adherence. The sensi-
tivity, specificity, positive and negative predictive values 
were: 20.5%, 91.7%, 44.4% and 78.0% respectively when 
TDM was compared to viral loads. The respective values 
for self-reported adherence were 2.6%, 97.5%, 25.0% and 
75.5%.
No reliable data on adherence and time of drug intake 
was available to support interpretation of the results. It 
was not possible to determine if the low concentrations 
were a true reflection of lower steady state concentra-
tions or because some patients had recently had a treat-
ment interruption and the TDM sample was collected 
while they had not yet achieved steady-state concen-
tration. Prospective studies with serial concentration 
measurements preceding a virologic outcome would 
yield additional information on the TDM approach. 
Our study was conducted in a clinical research facil-
ity, where TDM facilities and technical capacity are 
available and few centers are available for TDM in 
Africa. In contrast, viral load testing is more readily 
available in resource limited settings. If TDM were con-
firmed to provide additional value, feasibility and cost 
considerations for expansion of this test would need to 
be explored.
Conclusion
In agreement with previous studies, this study suggests 
that low drug levels of ART could contribute to viro-
logic failure. Prospective studies in resource limited 
settings are needed to investigate this relationship.
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